LIPOVELA

Product Overview

LIPOVELA, also marketed as LIPO VELA, is a South Korean lipolytic solution associated with HJ Corporations. Developed for the professional body-contouring market, its formulation combines phosphatidylcholine (PPC) and sodium deoxycholate with L-carnitine, vitamins, and additional skin-conditioning ingredients. LIPOVELA is commonly supplied in 10 mL vials, with ten vials per box, providing a total nominal volume of 100 mL.

LIPOVELA is commercially positioned for localized body-contouring applications. Its principal ingredient system combines phosphatidylcholine, a naturally occurring membrane phospholipid, with sodium deoxycholate, a bile salt known for its detergent-like and membrane-disrupting properties.

The formulation also includes ingredients associated with cellular metabolism, antioxidant activity, and skin conditioning. These include L-carnitine, B vitamins, glutathione, growth factor-related components, and cosmetic peptides, as identified in published product information.

This TEOSQUARE product page covers the standard LIPOVELA body-contouring formulation. It provides professional buyers with information about its composition, packaging, ingredient characteristics, and regulatory considerations. Commercial positioning does not independently establish clinical effectiveness or authorization for injection in a particular jurisdiction.

Key Features

• PPC + Sodium Deoxycholate: Combines phosphatidylcholine with sodium deoxycholate, two ingredients investigated in lipolytic formulations, with deoxycholate contributing established membrane-disrupting activity.
• L-Carnitine and B Vitamins: Contains ingredients involved in normal fatty acid transport and cellular metabolic pathways, including L-carnitine, riboflavin, and cyanocobalamin.
• Multi-Ingredient Formulation: Published product information identifies glutathione, vitamin C, growth factor-related components, and cosmetic peptides alongside the principal lipolytic ingredients.
• Body-Contouring Product Positioning: Marketed for professional aesthetic applications involving localized subcutaneous fat and body contour refinement.
• 10 mL Vial Presentation: Standard commercial packaging contains ten 10 mL vials, equivalent to 100 mL of solution per box.

Composition & Specifications

LIPOVELA is formulated around phosphatidylcholine and sodium deoxycholate. HJ Corporations identifies L-carnitine and riboflavin as additional components, while published product specifications describe a broader combination of vitamins, antioxidants, growth factor-related ingredients, and peptides.

Commercial materials describe high-purity PPC and sodium deoxycholate raw materials. These purity declarations must be distinguished from the actual concentrations of the ingredients in the finished solution.

Phosphatidylcholine (PPC)

Phosphatidylcholine is a naturally occurring phospholipid found in cellular membranes and lipoproteins. Its molecular structure contains both hydrophilic and hydrophobic regions, allowing it to participate in the organization of biological lipid membranes.

PPC plays physiological roles in membrane structure, lipid transport, and cellular metabolism. It has also been investigated as a component of injectable formulations intended for localized fat reduction, particularly in combination with sodium deoxycholate.

Published LIPOVELA commercial information reports a PPC quantity of 1,000 mg per 10 mL vial. However, this quantitative specification has not been conclusively verified against a manufacturer-issued certificate of analysis or complete formulation document.

The manufacturer's promotional materials also describe high-purity PPC raw material. Raw material purity should not be confused with the PPC concentration in the finished liquid solution.

Sodium Deoxycholate

Sodium deoxycholate is the sodium salt of deoxycholic acid, a naturally occurring secondary bile acid. It has amphipathic properties that allow it to interact with lipid-based cellular membranes.

At sufficient concentrations, sodium deoxycholate can disrupt membrane integrity and cause cell lysis. This cytolytic property is an important mechanism investigated in deoxycholate-containing fat-reduction formulations.

LIPOVELA product materials identify sodium deoxycholate with a reported raw material purity of 99%. The actual concentration of sodium deoxycholate in the finished product has not been independently established from authoritative quantitative documentation.

L-Carnitine and Vitamin B Complex

LIPOVELA contains L-carnitine and B vitamins, including riboflavin (vitamin B2) and cyanocobalamin (vitamin B12).

L-carnitine is involved in transporting long-chain fatty acids into mitochondria for beta-oxidation. Riboflavin participates in cellular metabolism through flavin-containing coenzymes, while vitamin B12 supports essential metabolic reactions.

These ingredients have established physiological functions, but their inclusion in LIPOVELA does not independently demonstrate accelerated local fat metabolism or enhanced clinical lipolytic effectiveness.

Glutathione and Antioxidant Ingredients

Glutathione is a naturally occurring tripeptide composed of glutamate, cysteine, and glycine. It participates in cellular antioxidant defense and reactions involving reactive oxygen species.

Published LIPOVELA formulations also include ascorbic acid, commonly known as vitamin C, which participates in antioxidant reactions and collagen biosynthesis.

These biochemical properties provide context for the formulation's antioxidant-related ingredient positioning. However, their presence does not establish that LIPOVELA prevents tissue damage, improves skin elasticity, or produces clinically demonstrated skin-brightening effects.

Growth Factor-Related Components

Published LIPOVELA ingredient information identifies epidermal growth factor (EGF), fibroblast growth factor 1 (FGF1), and insulin-like growth factor (IGF).

These signaling proteins are involved in cellular communication, proliferation, and tissue-maintenance processes. Their biological activity depends on molecular integrity, concentration, tissue exposure, and other formulation-specific factors.

The inclusion of growth factor-related ingredients does not independently establish improved collagen production, skin tightening, or enhanced tissue regeneration for the finished LIPOVELA solution.

Peptides and Additional Skin-Conditioning Ingredients

LIPOVELA product information identifies cosmetic peptides, including Palmitoyl Pentapeptide-4 and Palmitoyl Tetrapeptide-7.

Palmitoyl Pentapeptide-4 is a synthetic peptide investigated in selected cosmetic formulations for its relationship with skin appearance and extracellular matrix-associated pathways.

Palmitoyl Tetrapeptide-7 is another cosmetic peptide studied in the context of skin-conditioning formulations and selected inflammatory signaling processes.

Additional reported components include arginine, arbutin, and 1,2-hexanediol. These ingredients have different biochemical or formulation-related functions and should not be assumed to produce specific clinical outcomes when combined.

The published ingredient list provides useful product-identification information, but complete quantitative concentrations have not been established for all components. Professional buyers should confirm the finished formulation using the original manufacturer-issued documentation.

How LIPOVELA Is Formulated to Work

The scientific basis of LIPOVELA's lipolytic positioning involves the properties of phosphatidylcholine and sodium deoxycholate. Additional ingredients are associated with cellular metabolism and skin conditioning, although their contribution to the finished product's clinical performance has not been established.

Cellular Membrane Disruption

Sodium deoxycholate has detergent-like properties that enable it to interact with phospholipid membranes. At sufficient concentrations, it can disrupt membrane integrity and cause cellular injury or lysis.

Adipocytes are specialized cells that store triglycerides. Their membranes, like those of other mammalian cells, contain phospholipids that may be affected by cytolytic substances.

The membrane-disrupting activity of sodium deoxycholate is not inherently selective for adipocytes. Surrounding tissues may also be susceptible to injury.

Phosphatidylcholine and Lipid Interactions

Phosphatidylcholine contributes to the structure and organization of biological lipid membranes. PPC-deoxycholate combinations have been investigated in research involving localized adipose tissue reduction.

Scientific studies of selected PPC-deoxycholate formulations indicate that deoxycholate contributes substantially to their cytolytic activity. The role of PPC should therefore be distinguished from the direct membrane-disrupting effects of the bile salt.

Inflammatory Response and Tissue Remodeling

Cellular injury can initiate a localized inflammatory response involving macrophages and other immune cells. These cells participate in processing damaged cellular material and subsequent tissue remodeling.

These mechanisms have been investigated using certain injectable deoxycholate formulations. However, findings from other preparations cannot automatically establish equivalent effects, safety, or clinical performance for LIPOVELA.

Complementary Metabolic and Skin-Conditioning Ingredients

L-carnitine and B vitamins participate in normal cellular metabolism, while glutathione, vitamin C, and selected peptides have established biochemical or cosmetic research applications.

The inclusion of these components provides a multi-ingredient formulation concept. Their presence does not demonstrate clinically proven synergy, prevention of skin laxity, or predictable improvement in body contour.

The mechanisms described above concern established ingredient properties and related scientific research. They do not establish product-specific clinical effectiveness, treatment duration, or regulatory authorization for LIPOVELA.

LIPOVELA Product Characteristics

LIPOVELA is the standard body-contouring formulation within the LIPO VELA product portfolio. Its principal distinguishing characteristics include its PPC and sodium deoxycholate composition, additional metabolic and skin-conditioning ingredients, and 10 mL vial presentation.

• Body-Contouring Positioning: Marketed for professional aesthetic applications involving localized body fat rather than general weight management.
• PPC and Deoxycholate Combination: Contains two ingredients investigated in lipolytic formulations, with sodium deoxycholate providing established cytolytic activity.
• Multi-Component Formula: Includes L-carnitine, vitamins, glutathione, peptides, and growth factor-related ingredients according to published specifications.
• 10 mL Commercial Presentation: Supplied in a larger vial volume than the separately marketed LIPOVELA-V facial contouring formulation.

LIPOVELA is intended to be identified and evaluated as a distinct commercial formulation. Its packaging and product positioning should not be confused with the 5 mL LIPOVELA-V presentation.

Product positioning does not establish approval for any particular body area. The product's legal classification, permitted uses, and supporting clinical evidence must be independently verified.

Packaging & Product Presentation

LIPOVELA is commercially supplied as a liquid solution in individual 10 mL vials. The standard documented package contains ten vials, providing a total nominal volume of 100 mL.

The 10 mL × 10-vial configuration is documented in HJ Corporations-associated distribution materials and Korean commercial product listings.

Individual vials may also be offered separately by commercial suppliers. The selected selling unit should be verified against the original manufacturer packaging and applicable product documentation.

Container volume is a packaging specification, not a recommended administration quantity. The presence of a liquid solution in a vial does not independently establish authorization for injection.

Storage & Handling

Published LIPOVELA commercial documentation describes storage in a dark environment at temperatures between 5°C and 30°C, protected from direct sunlight. This numerical range is supplier-reported and should be verified against the original manufacturer labeling.

• Reported Storage Temperature: 5°C to 30°C, according to published Korean supplier information.
• Light Protection: Protect the product from direct sunlight and excessive light exposure.
• Original Packaging: Keep vials in their supplied packaging until required for legally permitted use.
• Container Integrity: Inspect the vial and closure for visible damage, leakage, or other signs of compromised packaging.
• Product Traceability: Verify the product name, batch number, expiration date, and manufacturer information.

Storage stability, shelf life, and handling requirements after opening must be confirmed using validated manufacturer instructions. Do not rely on third-party handling recommendations when official product documentation differs.

Safety & Regulatory Considerations

LIPOVELA contains sodium deoxycholate, a substance capable of disrupting cellular membranes. Products containing cytolytic ingredients require careful regulatory and professional evaluation because their effects are not inherently restricted to adipose tissue.

Potential Tissue Reactions

Potential adverse events associated with injectable lipolytic products include pain, swelling, bruising, inflammation, infection, persistent nodules, tissue necrosis, scarring, and injury to surrounding anatomical structures.

The risk profile of an individual product depends on its complete formulation, ingredient concentrations, manufacturing quality, authorized application method, and patient-specific factors.

Multi-Ingredient Formulation

LIPOVELA contains several additional reported ingredients, including L-carnitine, vitamins, glutathione, growth factor-related components, and peptides.

These ingredients do not independently establish that the product prevents inflammation, improves tolerability, protects surrounding tissues, or reduces adverse reactions associated with cytolytic substances.

Regulatory Authorization

The United States Food and Drug Administration has approved specific prescription deoxycholic acid products for defined indications. Such approvals are product-specific and do not extend automatically to other commercial lipolytic formulations.

US FDA approval for LIPOVELA has not been established. Likewise, commercial distribution in South Korea or other international markets does not independently demonstrate regulatory authorization for injection or body-contouring treatment.

Professional buyers should verify the legal product classification, manufacturer-issued composition, permitted administration route, contraindications, and applicable regulatory documentation before procurement or clinical consideration.

This information is intended for professional product identification and comparison. It does not constitute clinical guidance, establish patient suitability, or authorize the injection of an unapproved product.

Frequently Asked Questions